← All trials
NCT06773364
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Jan 14, 2025
- Last posted
- May 22, 2025
- Enrollment
- 2423
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Fudan UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.